prof.dr. M.J. IJzerman (Maarten)

van Delft, F. A., Schuurbiers, M. M. F., Muller, M., Burgers, S., van Rossum, H. H. , IJzerman, M. J., van den Heuvel, M. M. , & Koffijberg, H. (2023). Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. Tumor Biology. https://doi.org/10.3233/TUB-220022

van Delft, F. A. (2023). Optimizing the use of blood based biomarkers to improve the clinical management of advanced non-small cell lung cancer. [PhD Thesis - Research UT, graduation UT, University of Twente]. University of Twente. https://doi.org/10.3990/1.9789036557306

Rizvi, F., Wilding, H. E., Rankin, N. M., Le Gautier, R., Gurren, L., Sundararajan, V., Bellingham, K., Chua, J., Crawford, G. B., Nowak, A. K., Le, B., Mitchell, G., McLachlan, S. A., Sousa, T. V., Hudson, R. , IJzerman, M., Collins, A., & Philip, J. (2023). An evidence-base for the implementation of hospital-based palliative care programs in routine cancer practice: A systematic review. Palliative Medicine. https://doi.org/10.1177/02692163231186177

van Til, J. A. , Kip, M. M. A., Schatorjé, E. J. H., Currie, G., Twilt, M., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N., Yeung, R. S. M. , Groothuis-Oudshoorn, C. G. M. K., Warta, S., Marshall, D. A. , IJzerman, M. J., & UCAN CAN-DU, UCAN CURE consortia (2023). Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? Pediatric rheumatology online journal, 21(1), 69. [69]. https://doi.org/10.1186/s12969-023-00845-4

Drosdowsky, A., Lamb, K. E., Bergin, R. J., Boyd, L., Milley, K. , IJzerman, M. J., & Emery, J. D. (2023). A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research. Cancer epidemiology, 83, [102323]. https://doi.org/10.1016/j.canep.2023.102323

To, Y. H., Gibbs, P., Tie, J. , IJzerman, M., & Degeling, K. (2023). Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost effectiveness and resource allocation, 21(1), [11]. https://doi.org/10.1186/s12962-023-00422-2

O’Haire, S., Franchini, F., Kang, Y. J., Steinberg, J., Canfell, K., Desai, J., Fox, S. , & IJzerman, M. (2023). Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Scientific reports, 13(1), [4116]. https://doi.org/10.1038/s41598-023-31055-3

Fagery, M., Khorshidi, H. A., Wong, S. Q., Vu, M. , & IJzerman, M. (2023). Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review. PharmacoEconomics, 41(10), 1229-1248. https://doi.org/10.1007/s40273-023-01292-5

Currie, G. R. , Groothuis-Oudshoorn, C. G. M., Twilt, M. , Kip, M. M. A. , IJzerman, M. J., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R., & Marshall, D. A. (2023). What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey. Clinical rheumatology, 42(8), 2173-2180. https://doi.org/10.1007/s10067-023-06616-6

Behr, C. M., Oude Wolcherink, M. J. , IJzerman, M. J., Vliegenthart, R. , & Koffijberg, H. (2023). Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics, 41, 395-411. https://doi.org/10.1007/s40273-022-01238-3